Caribou Biosciences, Inc.
CRBU
$1.96
$0.084.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.01% | -3.13% | -41.62% | -91.45% | -7.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.01% | -3.13% | -41.62% | -91.45% | -7.75% |
| Cost of Revenue | -34.90% | 7.79% | -4.52% | 4.33% | -92.48% |
| Gross Profit | -6.87% | -24.88% | -0.24% | -464.75% | 106.46% |
| SG&A Expenses | -9.42% | -33.52% | 7.89% | -38.82% | 13.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.89% | -6.54% | -1.58% | -6.61% | 28.24% |
| Operating Income | 18.56% | 6.71% | -2.22% | -130.56% | -32.35% |
| Income Before Tax | -43.51% | 3.01% | -3.46% | -246.77% | -27.70% |
| Income Tax Expenses | -- | -- | -104.66% | -- | -- |
| Earnings from Continuing Operations | -43.51% | 3.01% | -2.85% | -246.77% | -27.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.51% | 3.01% | -2.85% | -246.77% | -27.70% |
| EBIT | 18.56% | 6.71% | -2.22% | -130.56% | -32.35% |
| EBITDA | 19.66% | 7.82% | -1.06% | -149.43% | -32.23% |
| EPS Basic | -39.35% | 6.54% | 0.23% | -221.11% | 13.17% |
| Normalized Basic EPS | -8.05% | 6.55% | 0.99% | -179.49% | 13.24% |
| EPS Diluted | -39.35% | 6.54% | 0.23% | -221.11% | 13.17% |
| Normalized Diluted EPS | -8.05% | 6.55% | 0.99% | -179.49% | 13.24% |
| Average Basic Shares Outstanding | 2.98% | 3.78% | 3.09% | 7.96% | 47.09% |
| Average Diluted Shares Outstanding | 2.98% | 3.78% | 3.09% | 7.96% | 47.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |